Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation
IL7R plays a critical role in shaping TME diversity across cancer types and holds promise as a relevant biomarker for predicting immunotherapy benefits.
Authors
- Kan Wu (ORCID: https://orcid.org/0000-0003-4796-6198)
- Jiawei Li (ORCID: https://orcid.org/0000-0001-7846-8963)
- Lucheng Zhu (ORCID: https://orcid.org/0000-0001-7298-4166)
- Minna Zhang (ORCID: https://orcid.org/0000-0003-1567-3788)
- Bing Xia (ORCID: https://orcid.org/0000-0003-3259-6139)
- Xueqin Chen (ORCID: https://orcid.org/0000-0002-0373-4785)
- Shenglin Ma (ORCID: https://orcid.org/0009-0006-2355-7938)
- Jiafeng Liang
Institutions
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1007/s12672-024-01357-7
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70